Jardine Matheson Buys I-MED Radiology for $3.4B

Hong Kong conglomerate Jardine Matheson Holdings Limited is set to acquire I-MED Radiology Network, Australia's largest diagnostic imaging provider, for a total enterprise value of AUS$3.4 billion (approximately $2.24 billion USD). The transaction marks a significant move for Jardine Matheson into the healthcare diagnostics sector, aligning with its strategy of investing in market-leading assets with strong growth potential.

The deal represents a substantial exit for European private equity firm Permira, which has held a controlling stake in I-MED since 2018. During Permira's ownership, I-MED underwent a significant digital and AI-driven transformation, expanding its network across Australia and into New Zealand and the United States through strategic acquisitions. The company now operates 215 clinics and performs over seven million patient procedures annually, offering a full spectrum of imaging services including MRI, CT, and X-Ray, alongside a leading teleradiology business, I-TeleRAD.

A key element of I-MED's evolution under Permira's stewardship was its early and ambitious adoption of artificial intelligence in radiology. The company's joint venture with Harrison.ai, a prominent medical imaging AI firm, has been instrumental in developing a comprehensive AI platform for diagnostics and image analysis. This technological integration has reportedly enhanced clinician efficiency, improved service delivery, and elevated the standard of diagnostic care, positioning I-MED as an innovator in the field.

This divestiture continues a strong period of realizations for Permira. The firm has recently completed successful exits from other portfolio companies, including Evelyn Partners and AltamarCAM earlier in 2026. The sale of I-MED underscores the value created through strategic operational improvements and technological advancements within the healthcare services sector, a market benefiting from structural tailwinds such as an aging population and increased focus on preventive medicine.

Dr. Shrey Viranna, CEO of I-MED Radiology Network, expressed pride in the company's journey with Permira, highlighting the growth in network, investment in clinical excellence, and pioneering work in AI-driven diagnostics. He anticipates further expansion under Jardine Matheson's ownership. Lincoln Pan, CEO of Jardine Matheson, emphasized I-MED's market leadership and the conglomerate's commitment to long-term growth and expansion into new markets, reinforcing the strategic importance of this acquisition within Jardine's healthcare vertical ambitions.

The transaction is subject to regulatory approvals and is anticipated to conclude later in 2026. This acquisition is expected to solidify I-MED's regional market leadership while providing Jardine Matheson with a robust platform for future growth in the rapidly evolving healthcare diagnostics industry.